Gail J. Roboz, MD, Weill Cornell Medical Center

Articles by Gail J. Roboz, MD, Weill Cornell Medical Center

Utilization of Second-Generation FLT3 Inhibitors in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

Second-Generation FLT3 Inhibitors in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

FLT3-Mutated AML: Midostaurin and Chemotherapy

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

FLT3-Mutated AML: Early Aggressive Therapy vs Transplant

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

FLT3 Genetic Alterations in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

Dr. Roboz on Impact of the FDA Approval of CTL019 in ALL

ByGail J. Roboz, MD, Weill Cornell Medical Center

August 30th 2017

Gail J. Roboz, MD, a professor of Medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the impact of the FDA approval of tisagenlecleucel (CTL019) in patients with acute lymphoblastic leukemia.

Dr. Gail Roboz on Molecular Mutations in MDS

ByGail J. Roboz, MD, Weill Cornell Medical Center

May 2nd 2015

Gail J. Roboz, MD, associate professor of Medicine, director, Leukemia Program, Weill Medical College of Cornell University, New York-Presbyterian Hospital, discusses the growing field of molecular mutations in myelodysplastic syndromes (MDS).

Dr. Roboz on Improving the Standard Treatment of AML

ByGail J. Roboz, MD, Weill Cornell Medical Center

November 30th 2012

Gail J. Roboz, MD, associate professor of medicine, director of the Leukemia Program at the Weill Medical College of Cornell University and the New York-Presbyterian Hospital in New York City, explains research into potential improvements to the standard treatment of AML.

Gail J. Roboz, MD, Weill Cornell Medical Center

Articles by Gail J. Roboz, MD, Weill Cornell Medical Center

Utilization of Second-Generation FLT3 Inhibitors in AML

Second-Generation FLT3 Inhibitors in AML

FLT3-Mutated AML: Midostaurin and Chemotherapy

FLT3-Mutated AML: Early Aggressive Therapy vs Transplant

FLT3 Genetic Alterations in AML

Dr. Roboz on Impact of the FDA Approval of CTL019 in ALL

Dr. Gail Roboz on Molecular Mutations in MDS

Dr. Roboz on Improving the Standard Treatment of AML

Trending on OncLive

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies

Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis